Guidelines for topical PUVA: a report of a workshop of the British photodermatology group
- PMID: 10651690
- DOI: 10.1046/j.1365-2133.2000.03237.x
Guidelines for topical PUVA: a report of a workshop of the British photodermatology group
Abstract
Psoralen photochemotherapy [psoralen ultraviolet A (PUVA)] plays an important part in dermatological therapeutics, being an effective and generally safe treatment for psoriasis and other dermatoses. In order to maintain optimal efficacy and safety, guidelines concerning best practice should be available to operators and supervisors. The British Photodermatology Group (BPG) have previously published recommendations on PUVA, including UVA dosimetry and calibration, patient pretreatment assessment, indications and contraindications, and the management of adverse reactions.1 While most current knowledge relates to oral PUVA, the use of topical PUVA regimens is also popular and presents a number of questions peculiar to this modality, including the choice of psoralen, formulation, method of application, optimal timing of treatment, UVA regimens and relative benefits or risks as compared with oral PUVA. Bath PUVA, i.e. generalized immersion, is the most frequently used modality of topical treatment, practised by about 100 centres in the U.K., while other topical preparations tend to be used for localized diseases such as those affecting the hands and feet. This paper is the product of a recent workshop of the BPG and includes guidelines for bath, local immersion and other topical PUVA. These recommendations are based, where possible, on the results of controlled studies, or otherwise on the consensus view on current practice.
Similar articles
-
British Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of psoralen-ultraviolet A therapy 2015.Br J Dermatol. 2016 Jan;174(1):24-55. doi: 10.1111/bjd.14317. Br J Dermatol. 2016. PMID: 26790656 No abstract available.
-
Psoralen cream plus ultraviolet A photochemotherapy (PUVA cream): our experience.J Eur Acad Dermatol Venereol. 2006 Feb;20(2):136-42. doi: 10.1111/j.1468-3083.2006.01378.x. J Eur Acad Dermatol Venereol. 2006. PMID: 16441619
-
Audit of the use of psoralen photochemotherapy (PUVA) and narrowband UVB phototherapy in the treatment of psoriasis.J Dermatolog Treat. 2005 Apr;16(2):108-12. doi: 10.1080/09546630510033212. J Dermatolog Treat. 2005. PMID: 16019625
-
Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis. Do the known risks now outweigh the benefits?Drug Saf. 1999 Apr;20(4):289-97. doi: 10.2165/00002018-199920040-00001. Drug Saf. 1999. PMID: 10230579 Review.
-
Guidelines for bath PUVA, bathing suit PUVA and soak PUVA.Indian J Dermatol Venereol Leprol. 2015 Nov-Dec;81(6):559-67. doi: 10.4103/0378-6323.168336. Indian J Dermatol Venereol Leprol. 2015. PMID: 26515832 Review.
Cited by
-
UVA/UVA1 phototherapy and PUVA photochemotherapy in connective tissue diseases and related disorders: a research based review.BMC Dermatol. 2004 Sep 20;4(1):11. doi: 10.1186/1471-5945-4-11. BMC Dermatol. 2004. PMID: 15380024 Free PMC article. Review.
-
Topical treatments for scalp psoriasis.Drugs. 2008;68(16):2293-302. doi: 10.2165/0003495-200868160-00003. Drugs. 2008. PMID: 18973394 Review.
-
Efficacy and Safety of Alitretinoin for Chronic Hand Eczema in Korean Patients.Ann Dermatol. 2016 Jun;28(3):364-70. doi: 10.5021/ad.2016.28.3.364. Epub 2016 May 25. Ann Dermatol. 2016. PMID: 27274636 Free PMC article.
-
Phenylpropanoid composition in fig (Ficus carica L.) leaves.J Nat Med. 2017 Oct;71(4):770-775. doi: 10.1007/s11418-017-1093-6. Epub 2017 Jun 6. J Nat Med. 2017. PMID: 28589249
-
A Perspective on the Use of NB-UVB Phototherapy vs. PUVA Photochemotherapy.Front Med (Lausanne). 2018 Jul 2;5:184. doi: 10.3389/fmed.2018.00184. eCollection 2018. Front Med (Lausanne). 2018. PMID: 30013973 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical